The Lancet in conversation with

Richard Horton on the Oxford vaccine phase 3 trial

The Lancet

Editor-in-chief of The Lancet, Richard Horton, discusses the results of the Oxford vaccine's phase 3 trial.

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv